君实生物2025年净利预亏8.73亿元，同比减亏

Core Viewpoint - Junshi Biosciences (688180) forecasts a net profit attributable to shareholders of approximately -870 million yuan for 2025, indicating a significant reduction in losses compared to the previous year, with a decrease of about 408 million yuan or 31.85% year-on-year [1] Group 1 - The company expects to report a net loss for 2025, but the loss amount is significantly narrowed compared to the same period last year [1] - The improvement in financial performance is attributed to the implementation of the "quality improvement and efficiency enhancement" action plan, which has notably enhanced commercial capabilities while strengthening cost control and resource focus [1] - During the reporting period, the company maintained efficient progress on its core pipeline while controlling expenses, advancing several innovative drugs with international market competitiveness, including JS207, JS212, and JS213 [1]